ESC-EHRA-FinalProgramme-2017

E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E EUROPACE FINAL PROGRAMME 18-21 June CARDIOSTIM Vienna, Austria Connect www.escardio.org/EUROPACE #ehraeuropace With the participation of the ESC Working Groups on e-Cardiology and Grown-up Congenital Heart Disease and in conjunction with the 41st Annual Meeting of the ESC Working Group on Cardiac Cellular Electrophysiology E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Building Overview E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Welcome Address EHRA EUROPACE - CARDIOSTIM 2017 promises to be a highly successful congress! The EHRA Scientific Programme Committee has developed a compelling programme designed to provide attendees with the latest in science and education in the field of cardiac rhythm disorders and therapies During this four days congress, highly acclaimed scientific sessions will cover all aspects of pacing and electrophysiology Delegates will also have the chance to discover new research, learn from world renowned experts and exchange with colleagues and peers Dedicated sessions for allied professionals, young electrophysiologists, and women in electrophysiology will be delivered and once again, the congress will be joined by colleagues from the ESC Working Groups on e-Cardiology and on Grown-up Congenital Heart Disease as well as the 41st Annual Meeting on Cardiac Cellular Electrophysiology We look forward to welcoming you to the beautiful city of Vienna, and making this congress another success! Prof Michael Glikson (IS) EHRA Scientific Programme Chairperson Prof Helmut Pürerfellner (AT) EHRA Scientific Programme Vice-Chairperson Dr Arnaud Lazarus (FR) Cardiostim Scientific Programme Chairperson Prof Pierre Jais (FR) Cardiostim Scientific Programme Vice-Chairperson E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Scientific Programme Committees Prof Michael Glikson (IS) Prof Helmut Pürerfellner (AT) EHRA Scientific Programme Chairperson EHRA Scientific Programme Vice-Chairperson Abstract Chairs Catheter Ablation Dr Alessandro Proclemer (IT) Prof Christian Wolpert (DE) Dr Roy Beinart (IL) Ass Prof Martin Martinek (AT) Prof Harry Crijns (NL) AF Summit Dr Luigi DiBiase (IT) Dr Christopher Piorkowski (DE) Allied Professionals Dr Jenny Tagney (GB) Prof Donna Fitzsimons (GB) Mrs Lynne Hinterbuchner (AT) Basic/Translational Science/Genetics Dr Carlo Napolitano (IT) Prof Joachim Ehrlich (DE) Dr David Arnar (IS) Cardiovascular Implantable Cardiostim Representatives Dr David Hayes (USA) Prof Win Shen (USA) Dr Pierre Bordachar (FR) Dr Frederic Sacher (FR) Prof Vincent Probst (FR) Prof Mark O’Neill (GB) Dr Christine Alonso (FR) Dr Hubet Cochet (FR) Prof Didier Klug (FR) Dr Elad Anter (USA) Electronic Devices Dr Etienne Pruvot (CH) Dr Michele Brignole (IT) Prof Frederic Anselme (FR) Prof Jean Claude Deharo (FR) Prof Prashanthan Sanders (AUS) Dr Francis Murgatroyd (GB) Prof Jagmeet Singh (USA) Ass Prof Moti Haim (IL) Prof David Wilber (USA) E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Dr Arnaud Lazarus (FR) Prof Pierre Jais (FR) Cardiostim Scientific Cardiostim Scientific Programme Chairperson Programme Vice-Chairperson Clinical EP Pediatric / Adult Congenital Heart Disease Prof Sami Viskin (IL) Prof Jan Janousek (CZ) Dr Laurent Pison (NL) Dr Joachim Hebe (DE) Prof Richard Schilling (GB) Dr Nico Blom (ML) Prof Isabel Deisenhofer (DE) GUCH WG rep - G Diller (DE) E-cardiology WG rep - Prof Goran Krstacic (HR) Heart Failure Prof Giuseppe Boriani (IT) Ass Prof Carsten Israel (DE) Regulatory /Health Politics / Education Dr Francisco Leyva (GB) Prof Giovanni Fattore (IT) Prof Paulus Kirchhof (GB) Dr Angel Moya (SP) Dr Giuseppe Stabile (IT) Dr Eyal Nof (IL) Scientific documents Prof Gregory Y H Lip (GB) Innovation Prof Frits Prinzen (NL) VT/VF Summit Prof Antonio Beruezzo (SP) e-Health Summit Prof Martin Cowie (UK) Women in EP Prof Andrea Sarkozy (BE) Lead and Device Management Summit Young EP Dr Maria Grazia Bongiorni (IT) Assist Prof Valentina Kutyifa (USA) EUROPACE E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Sunday - Day CA RD IO STIM 18-21 June Vienna, Austria d Could exercise-base onalised? rehabilitation be pers It subgroup of patients.” remains unclear whether particular patient subgroups with heart failure would from benefit more or less exercise-based rehabilitation than others, and therefore could healthcare resources efficiently more be targeted patient data meta-analysis, that he od Taylor (University Professor Taylor said the original patient II of Exeter Medical in and his ExTraMATCH anonymised data is, to and School, UK) and collaborators “are excited essence, reconstructed this colleagues previously be able bring together reorganised, and analysed a level Prof conducted a trial-level data set, which offers of as if one mega-trial that Rod Taylor, University metaanalysis of exerciseof statistical precision UK Taylor and an international which Exeter Medical School, previously had in have haven’t based rehabilitation, we collaborators of team 20 showed improvements our riallevel meta-analysis I collated data from life benefits and is a Class than in patient quality of address this subgroup trials, totalling more n of the ESC to hospital answers in recommendatio patients and reductions question” to provide one 4000 heart failure and clear Guidelines, only around weeks admissions but no for patients, clinicians patients who underwent ≥3 in five heart failure makers alike and evidence of an all-cause policy training of exercise across Europe currently at mortality benefit had reported outcomes Late Breaking Trials receive it However, Prof Taylor ≥6 months III: Focus on trial level Prof Taylor observed: said that “this trial Prof Taylor said that updates, registries have “We wanted to address one analysis study may s this is necessary as and meta-analyse the question of whether in lacked statistical power of the “big challenges” Monday 23 May we should be prescribing that, and had to deal with 08:30 - room Paris our heart cardiology today is follow rehabilitation to all studies of differing a although exercise-based failure patients or only patient up duration” He explained rehabilitation offers that, with an individual sed of whether exercise-ba Tomorrow, the questiontargeted to specific heart failure patient be resources will be rehabilitation could rationalise healthcare the results of groups and thus help al researchers present answered when internation data meta-analysis their individual patient R Quality of life hope for HFpEF patients treatment that improves for the first time, a fraction (HFpEF) on the brink of having, preserved ejection Clinicians could be with heart failure and quality of life in patients be attributed to presented findings that will be hat is the hope of study Trials II: of the Late Breaking this morning as part failure session by Burkert Focus on chronic heart izin Berlin, Germany) endpoint Pieske (Charité – Universitätsmed a pre-specified exploratory The results are from dosea placebo-controlled of SOCRATESPRESERVED, guanylate cyclase (sGC) oral soluble finding study of the which looked in HFpEF patients, stimulator vericiguat ic effects and pharmacodynam at the safety, tolerability, 2.5 mg, mg, and vericiguat 1.25 mg, pharmacokinetics of T of life could improved central hemodynamics to with vericiguat, leading improved clinical function,” primary said Prof Pieske The is change in – endpoint of the study Burkert Pieske, Charité levels zin logtransformed NT-ProBNP at 12 weeks The Universitätsmedi and left atrial volume Germany the patients’ Berlin, researchers also assessed the Kansas City using status as the health (the KCCQ), as well Cardiomyopathy Questionnaire of appropriate endpoints “The selection ED-5Q instrument of debate,” adds studies remains a matter in HFpEF phase II 10 mg once daily the impact of analysis is to examine Here, the aim of this patients quality of life in 447 Prof Pieske vericiguat is found vericiguat on patient-reported measure because, are presented today, is a very important If, when the results life compared to with a HFpEF “This ejection fraction, improved quality of failure with preserved to have significantly be “a clinically particularly in heart “at the said that this would said Prof Pieske, adding placebo, Prof Pieske the first time, quality of life is poor,” means to improve finding because, for have any approved relevant and important a new therapeutic moment we not that there might be and quality of life.” this would indicate patients.” patient reported outcomes in cyclic quality of life in these increase an to leads approach to improved Stimulation of sGC mediates heart (GMP), which in turn III: Focus on chronic function, guanosine monophosphate Late Breaking Trials vascular function, diastolic room Paris 08:30 vasodilation, May 22 improved into the systemic failure Sunday ventricular ejection and coupling of left improved quality words, a rationale for circulation “In other Download App the “EHRA 2017” Mobile Read about the scientific highlights of the day, find exclusive scientific articles and other daily news MME IN TODAY’S PROGRA II: Late Breaking Trials heart failure:   Focus on chronic 08:30 – room Paris New ESC Guidelines   Focus on comorbidities: 11:00 – room London the new guidelines:   A global view on Rome divide: 16:30 – room crossing the great Need for global alliance 14:15 – room Rome against heart failure: Mobile App Voting: failure: scenarios in heart   Challenging clinical 16:30 – room Paris Basic Science Track: – room Barcelona   sessions today in the Agora Abstract sessions Award at 08:30   Nursing Investigators Award:   Young Investigators Clinical at 11:00 Award:   Young Investigators Basic Science at 14:15 16:30   Clinical Case at Award Ceremony at 16:00 On the HFA Stand CASE AREA VIRTUAL on a and interactive case Experience a virtual the the Coffee Breaks in digital simulator during Virtual Case Area! Internet connection Free Wi-Fi is available at the congress center however please note that connectivity is subject to the volume of userWi-Fi SSID Wi-Fi Name : ehra-congress Wi-Fi Password : ehra-congress Certificates • For attendance – available from the registration desks as of Tuesday 20 June • For presentation – available for abstract presenters at the poster assistance desk in the poster area Continuing medical education (CME) EHRA EUROPACE – CARDIOSTIM 2017 is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems net EHRA EUROPACE – CARDIOSTIM 2017 is designated for a maximum of 20 hours of European external CME credits Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category Credits™ Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Language The official language during the congress is English All lectures & presentations (apart from four sessions in German, on Sunday, in the Nurse and Allied Professionals track) will be held in English No translation is available Programme Changes / Date of print The date of print is 17 May 2017 For the most updated version of the programme, visit the Scientific Programme & Planner or download the Mobile App Security Please ensure your badge is visible at all times and comply with security controls that you may be subject to within the congress venue Information points For any other information (medical care, lost & found…) please address the organisers at the registration Cloakroom Leave your belongings (free of charge) at the cloakroom Catering Refreshments are provided during official coffee breaks and at the Networking Reception Cash bars are available throughout the venue E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E INDUSTRY @ EHRA EUROPACE - CARDIOSTIM ACKNOWLEDGEMENTS The European Heart Rhythm Association wishes to express its sincere appreciation to all exhibitors, industry partners and sponsors mentioned below, who have contributed to the success of EHRA EUROPACE - CARDIOSTIM 2017 in a variety of ways and initiatives Abbott Cardiac Rhythm News Access Point Technologies EP CardioFocus, Inc ACUTUS MEDICAL Cascade Refining Inc American College of Cardiology CIRCA Scientific, LLC Arrhythmia Alliance CNSystems Medizintechnik AG Asia Pacific Heart Rhythm Society Cook Medical Atricure Daiichi Sankyo Europe GmbH Bardy Diagnostics EBR Systems Inc Baylis Medical FibriCheck Biosense Webster Finapres BIOTRONIK Galgo Medical S.L Bittium Health in Code SL Boehringer Ingelheim International GmbH HealthWatch LTD Boston Scientific International Heart Rhythm Society E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Impulse Dynamics Radcliffe Cardiology Imricor Rooti Lindacare Schwarzer Cardiotek LivaNova (formerly Sorin Group) Siemens Healthineers MedFact engineering GmbH Spectranetics International b.v MEDICO SPA St Jude Medical is now Abbott Medtronic Stereotaxis Merit Medical Synaptic Medical MicroPort EP Vitatron National Manufacturing Co., Inc Wisepress Online Bookshop NUUBO World Society of Arrhythmias (WSA) OSYPKA AG ZOLL LifeVest Oxford University Press PREVENTICUS GmbH E H R A E U R O PA C E - C A R D I O S T I M 2017 F I N A L P R O G R A M M E Exhibition At the heart of the congress centre, the exhibition will be a central hub for scientific discussion and exchange to have the opportunity to interact with key industry experts on critical areas of development and research in cardiovascular products and therapies.The exhibition will provide you with a unique opportunity to catch a glimpse of the continuous therapeutic and technological developments in the electrophysiological discipline The fight against cardiovascular disease is a shared mission Our industry partners offer a rich educational programme to delegates throughout the congress Discover the wide variety of activities from educational sessions to stand activities 10